Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3611-3620 Newer>

Pharmaceutical Executive April 1, 2007 Fard Johnmar	Alternative Media: Mastering Social Media Pharma agencies are buzzing about social media tools such as blogs, podcasts, and interactive healthcare forums, but few firms really know how to make these online initiatives work.
Pharmaceutical Executive April 1, 2007 Alexandra Drane	Direct to Consumer: The Not-So-Cold Call A number of pharmaceutical companies are using phone-based, speech-enabled outreach to build share and to drive brand recognition and loyalty.
Pharmaceutical Executive April 1, 2007	Sales Management: The New BioPharma Representative With today's sales force in flux, pharma is looking to a new sales elite.
Pharmaceutical Executive April 1, 2007 Sarah Houlton	Global Report: If It Ain't Broke Under the UK's pricing scheme, drug prices have dropped by 21% in 10 years. Is it really time for a change?
Pharmaceutical Executive April 1, 2007	Thoughtleader: Melissa Brown, Center for Value-Based Medicine Here, co-author Melissa Brown discusses her book Evidence-Based to Value-Based Medicine and what's driving the move toward value-based medicine, how it will affect pharma, and why executives should embrace it.
Pharmaceutical Executive April 1, 2007	Deals: No IPO for Organon Akzo Nobel's plans to spin off its Organon Biosciences unit... Oxford BioMedica will acquire the privately held Oxxon Therapeutics... Jazz Pharmaceuticals has filed a registration statement with the SEC for... etc.
Pharmaceutical Executive April 1, 2007 Porth & Sillup	Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news.
Pharmaceutical Executive April 1, 2007 Bill Trombetta	Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes?
The Motley Fool April 11, 2007 Brian Lawler	Adolor: Down and Out? The drug developer announces dour clinical trial results. Shares of Adolor crashed nearly 60% on the news.
The Motley Fool April 11, 2007 Brian Lawler	Get Rich With These Guys Regardless of what type of long-term investment strategy you use, finding companies created under the auspices of proven entrepreneurs such as Moll, Zaffaroni, and Mann and then sticking with them for the long run is one path to investing riches.
<Older 3611-3620 Newer> Return to current articles.